All In Biotech

Drug Trial Radar · NCT03082235

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Sep 7, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Mar 3, 2017

Primary completion

Oct 11, 2017

Study completion Oct 11, 2017

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
First posted
Mar 17, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Study E6742-A001-001 is a randomized, double-blind, placebo-controlled, single ascending dose study conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending oral doses of E6742 in healthy adult participants.

Conditions

  • Healthy Participants

Interventions

  • E6742Drug

    gelatin capsules

  • PlaceboDrug

    gelatin capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with any serious adverse event and number of participants with any non-serious adverse eventTime frame: from Screening up to Day 7
  2. Mean maximum observed concentration (Cmax) of E6742 and the metabolite ER-1132963 in plasmaTime frame: Days 1 to 7
  3. Time at which the highest drug concentration occurs (tmax) for E6742 and the metabolite ER-1132963 in plasmaTime frame: Days 1 to 7
  4. Area under the concentration-time curve from zero time to 24 hours postdose (AUC[0-24h]) E6742 and the metabolite ER-1132963 in plasmaTime frame: Days 1 to 7
  5. Area under the concentration-time curve from zero time to 72 hours postdose (AUC[0-72h]) for E6742 and the metabolite ER-1132963 in plasmaTime frame: Days 1 to 7
  6. Area under the concentration-time curve from zero time to time of last quantifiable concentration (AUC[0-t]) for E6742 and the metabolite ER-1132963 in plasmaTime frame: Days 1 to 7
  7. Area under the concentration-time curve from zero time extrapolated to infinite time (AUC[0-inf]) for E6742 and the metabolite ER-1132963 in plasmaTime frame: Days 1 to 7
  8. Terminal elimination phase half-life (t1/2) for E6742 and the metabolite ER-1132963 in plasmaTime frame: Days 1 to 7
  9. Apparent total clearance following extravascular administration (CL/F) for E6742 in plasmaTime frame: Days 1 to 7
  10. Apparent volume of distribution at terminal phase (Vz/F) for E6742 in plasmaTime frame: Days 1 to 7
  11. AUC metabolite to E6742 ratio following molecular weight correction to E6742 equivalents in plasmaTime frame: Days 1 to 7
  12. Amount of unchanged drug excreted in urine (Ae) for E6742 and the metabolite ER-1132963Time frame: Days 1 to 7
  13. Renal clearance (CLR)Time frame: Days 1 to 7

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Parexel International

    Glendale, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.